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Introduction. Liraglutide (L) is the analogue of human glucagon-like peptide 1 which stimulates 
glucose-dependent insulin secretion and can modify the level of inflammatory biomarkers.
L can influence NF-kB inflammatory cascade, but the mechanisms of anti-inflammatory activities 
of L remain to be determined. In animal models L influenced an activity of Sirtuin l(SIRTl). 
Moreover, recent evidences strongly suggest that SIRT1 up-regulation may serve as a potent 
therapeutic approach against development and progression of diabetic complications. The aim of this 
study was to investigate L effects directed on the pro-inflammatory NF-kB pathway and expression of 
SIRT1 in obese patients with type 2 diabetes mellitus (DM).
Materials and Methods. 15 obese patients with type 2 diabetes were studied, all using 
metformin (1-2 g/day) and sulfonylurea (glimiperide). All patients received L 1.2 mg daily add-on to 
stable therapy for 6 weeks. Blood samples were collected before, 6 weeks after start of treatment and 
after an overnight fast 6 weeks after stopping L, mononuclear cells (MNC) were isolated. The mRNA 
expressions of TNF-a, TLR2, TLR4, NODI, 1L-2 and SIRT1 were measured in MNC by RT-PCR. 
Ceruloplasmin concentration was measured in plasma by photometric method.
Results. In this add-on pilot clinical investigation we received new data that L can inhibit 
proinflammatory NF-kB pathway by increased SIRT1 expression in obese patients with type 2 DM 
improving metabolic profile. The mRNA expression in MNC of TNF-a, IkB, TLR2, TLR4, and 
plasma ceruloplasmin fell after 6 weeks of L. Expressions of IL-2 and NOD-1 were stable. There was 
a significant increase of SIRT1 mRNA expression. The mRNA expression in MNC of TNF-a, IkB, 
TLR2, TLR4, NODI, SIRT1 and ceruloplasmin concentrations did not reverse to baseline levels after 
6 weeks stopping of L treatment. IL-2 expression decreased in comparison with basic level.
Conclusions. L has a potent anti-inflammatory effect as do GLP-1 agonists due to inhibition 
of NF-kB pathways and up-regulate SIRT1 expression, down-regulating pro-inflammatory factors 
including cytokines (TNF-a), extra- and intracellular receptors (TLR2, TLR4), and inflammation markers 
such as ceruloplasmin. Long lasting effects of L can be mediated by epigenetic regulation of NF-kB 
pathway by SIRT-1.
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INTRODUCTION
Liraglutide (L) is the analogue of human 
glucagon-like peptide 1 which stimulates glucose- 
dependent insulin secretion and can modify cardio­
vascular risk biomarkers such as hs-CRP, IL- 6, 
and TNF-a [1]. Another analogue of GLP-1 exenatide 
has a potent and rapid anti-inflammatory effect 
with a significant reduction in reactive oxygen 
species generation and the mRNA expression of 
several inflammatory mediators (TNF-a, JNK-1, 
TLR-2, TLR-4, IL-1, SOCS-3) in mononuclear 
cells [2]. The inhibitor of the enzyme dipeptidyl 
peptidase TV, which degrades GLP-1, led to the 
decrease of TLR-2, IKKb expression and nuclear 
factor-kB (NF-kB) binding [3].
Due to these data L can influence NF-kB 
inflammatory cascade, but the mechanisms of anti­
inflammatory activities of L remain to be deteimined. 
One possible way that L can influence an activity 
of some deacetylases because L modified an 
activity of Sirtuin l(SIRTl) in several cell types in 
animal models [4-8]. On the other hand, recent 
evidences strongly suggest that SIRT1 up-regulation 
may serve as a potent therapeutic approach against 
development and progression of diabetic complications 
[9]. Taking together these data suggests that L can 
provide anti-inflammatory activity connected with 
an inhibition of NF-kB pathway mediated by up- 
regulation of STRT1.
The aim of this study was to investigate L 
effects directed on pro-inflammatory NF-kB pathway
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and expression of SIRT1 in obese patients with 
type 2 diabetes mellitus (DM).
MATERIALS AND METHODS
This is a single-center, add-on prospective 
study. Fifteen obese patients with type 2 DM with a 
glycosylated hemoglobin (HbAlc) between 6.04 
and 9.7% participated in this study. None of the 
subjects had any microvascular or macrovascular 
complications of diabetes. All patients were on 
stable doses of oral antidiabetic medications and 
had stable weight for 4 weeks before the study. All 
patients were on metformin (1-2 g/d), and 4 patients 
were on sulfonylureas (glymepiride 2 mg/d). The
dose of statins and angiotensin converting enzyme 
inhibitors were not changed during the study. None 
of the subjects were on thiazolidinediones, anti­
oxidants, or nonsteroidal anti-inflammatory drugs. 
Patients’ demographic data are summarized in 
Table 1. All patients met with the dietitian and 
certified diabetes educator on 4 weeks before the 
study. General dietary recommendations as per 
American Diabetes Association guidelines were 
made to all subjects. All patients received L 1.2 mg 
daily add-on to stable therapy for 6 weeks. Blood 
samples were collected before, 6 weeks after start 
of treatment and 6 weeks after the stop of L after an 
overnight fast. The protocol was approved by the 
Ethic Committee of the University. An informed 
consent was signed by all subjects.
Table 1
Patient’s demographic and clinical data at baseline, after 6 weeks of 1.2 mg liraglutide and 6 weeks after the stop of L
Time points
Baseline At 6 weeks of L At 6 weeks after the stop of L
N (males) 15(4) 15(4) 15(4)
Age (yr) 54.56±7.15


























Blood samples were collected in Na-EDTA 
and carefully layered on ficoll-urograpfine gradient. 
Samples were centrifuged and the MNC band was 
harvested and washed twice with Hanks’ balanced 
salt solution. This method provides yields greater 
than 95% MNC in the preparation.
Quantification ofTLR-2, TLR-4, NOD-1, 
TNFa, 1L-2, IkB and SIRT1 expression 
The mRNA expression of TLR-2, TLR-4, 
NOD-1, TNFa, 1L-2, IkB and SIRT1 was measured 
in MNC by RT-PCR. Total RNA was isolated 
using commercially available “RIBO-sole-C” (Inter 
LabService LTD, Russian Federation). Real-time 
RT-PCR was performed using D-256 (DNA- 
Technology, Russian Federation) system, kit for 
reverse transcription, Sybr Green Master Mix and 
gene-specific primers (Table 2) (Sintol, Russian
Table 2
Primer sequences for mRNA measurement
Genes Primers
TLR4 F: 5’-AAGCCGAAAGGTGATTGTTG-3’ 
R: 5’-CTGAGCAGGGTCTTCTCCAC -3’
TLR2 F: 5'-TCTCCCATTTCCGTCTTTTT -3'
R: 5'-GGTCTTGGTGTTCATTATCTTC -3'
SIRT1 F:5’ - GCT GGC CTA ATA GAG TGG CAA - 3’ 
R:5’ - CTC AGC GCC ATG GAAAAT G - 3’
NODI F:5* - CTT CTG GTC ACT CAC ATC CGC A - 3’ 
R:5’ - TGG GCA TAG CAC AGC ACG AAC - 3’
P-actin F:5’ - ACC AAC TGG GAC GACATG GA - 3’ 
R:5’ - CCA GAG GCG TAC AGG GAT AG - 3’
TkBa F: 5’ - GGCTGAAGAAGGAGCGGCTA - 3’ 
R: 5’ - CCA TCT GCT CGT ACT CCT CG -3’
TNF-a F:5’ - AAC CTC CTC TCT GCC ATC AA - 3’ 
R:5’ - GGA AGA CCC CTC CCA GAT AG - 3’
IL-2 F:5’ - CAA CTC CTG TCT TGC ATT GC - 3’ 
R:5’ - GCT CCA GTT GTA GCT GTG TT - 3’
GAPDH F: 5’ - GGC CTC CAA GGA GTA AGA CC - 3’ 
R: 5’ - AGG GGA GAT TCA GTG TGG TG - 3’
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Federation). The expressions of TLR-2, TLR-4, 
NOD-1, TNFa, IL-2, IkB and SIRT1 were 
detectable as 2‘AQ. All the values were normalized 
to the expression of housekeeping genes action 
and GAPDH.
Plasma measurements
Glucose, ceruloplasmin and total cholesterol 
concentrations were measured in plasma by the 
photometric method. HbAlc concentration was 
measured by kits from BioSystems, Spain.
Statistical analysis
Statistical analysis was conducted using Sigma 
Stat software (SPSS Inc., Chicago, TL). All data are 
represented as mean ± SE. Paired t test and 
Student’s t test were used where appropriate.
RESULTS
Baseline characteristics
Fifteen subjects received L -  eleven females 
and four males, mean age 54.56 ±7.15 yr; mean 
body mass index (BMI) 41.07 ± 6.38 kg/m2, mean 
HbAlc 7.79 ± 0.78% (Fig. 1), fasting glucose -  
8.46 ± 1.80 mmol/L, total cholesterol -  6.62 ± 
1.34 mmol/L, ceruloplasmin -  253.92 ± 16.54 mg/L. 
Patients had systolic blood pressure -  150.0+12.5 
and diastolic blood pressure -  94.1 ± 7.0 mm Hg. 
Patients’ baseline characteristics are summarized in 
Table 1.
Effect o f L on metabolic indices
BMI decreased within 6 weeks of the 
administration of L 1.2 mg daily to 38.94 ± 
4.93 kg/m2 (p = 0.006) (Fig. 1,A). After the 
treatment with L, HbAlc fell significantly from 
7.79 ± 0.78 to 7.12 ± 0.85 % (P = 0.0050) (Fig. 1, B), 
fasting glucose -  from 8.46 ± 1.80 to 6.73 ± 
1.05 mmol/L (P = 0.0071), total cholesterol -  from 
6.62 ± 1.34 to 6.07 ± 0.74 mmol/L (P = 0.0172), 
ceruloplasmin -  from 253.92 ± 16.54 to 236.38 ± 
16.09 mg/L (P = 0.0000). Blood pressure decreased 
significantly: systolic blood pressure -  from
150.0 ± 12.5 to 140.9 ± 8.0 (P = 0.0015) and 
diastolic blood pressure -  from 94.1 ± 7.0 to 87.9 ±
4.0 (P = 0.0015) mm Hg (Table 1).
At 6 weeks after the stop of L, BMI 
decreased from 38.94+4.93 to 37.62 ± 4.70 kg/m2
(P = 0.0004), HbAlc fell significantly from 7.12 ± 
0.85 to 6.66 ± 0.68% (P = 0.0030) (Fig. 1), fasting 
glucose -  from 6.73 ± 1.05 to 5.70 ± 0.74 mmol/L 
(P = 0.0008), total cholesterol -  from 6.07 ± 0.74 to 
5.52 ± 0.32 mmol/L (P = 0.0043), ceruloplasmin -  
from 236.38 ± 16.09 to 227.58 ± 22.41mg/L (P = 
0.0145). Blood pressure decreased insignificantly.
Effect o fL  on TLR-2, TLR-4, NOD-1, TNFa, 
IL-2, IkB and SIRT1 gene expressions 
Peripheral blood MNCs had a relatively low 
expression of TNFa (0.11 ± 0.12), 7L-2(0.14 ± 0.2), 
IkB (0.06 ± 0.06; (Table 3), TLR-2 (0.421 ± 0.126), 
NOD-1 (0.047 ± 0.027), and SIRT1 (0.008 ± 0.008) 
(Fig. 2 A, B, C, D) genes in comparison with the 
housekeeping genq.TLR-4 gene expression was 
higher (1.658 + 1.211).
Table 3
The mRNA expression of TNFa, IL-2, IkB at baseline, after 
6 weeks of 1.2 mg liraglutide and 6 weeks after the stop of L
2~ACt
Time points
Baseline At 6 weeks of L At 6 weeks after the stop of L
















After 6 weeks of treatment with L, TLR-2 
expression decreased significantly from 0.421 ± 
0.126 to 0.286 ± 0.087 (P = 0.0000), TLR-4 from 
1.658 + 1.211 to 1.125 + 0.787 (P = 0.0011), TNFa 
from 0.11 ±0.12 to 0.09 + 0.09 (P = 0.017241), IkB 
from 0.06 ± 0.06 to 0.04 ± 0.05 (P = 0.005127). 
SIRT1 expression increased significantly from 
0.008 ± 0.008 to 0.02 ± 0.01 (P = 0.000630). 
Expressions of IL-2 and NOD-1 were stable.
At 6 weeks after the stop of L, TLR-2 
expression still decreased significantly from 
0.286 ± 0.087 to 0.195 + 0.134 (P = 0.0451), TLR-4 
from 1.125 ± 0.787 to 0.439 ± 0.196 (P = 0.0020), 
NOD-1 from 0.073 ± 0.072 to 0.014 ± 0.016 (P = 
0.0063), TNFa from 0.09 ± 0.09 to 0.06 ± 0.07 (P = 
0.005145). SIRT1 and IkB expressions were stable. 
IL-2 expression decreased in comparison with 
basic level.
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Figure 1. The mean values of BMI (A) and HbAlc (B) at baseline in obese Patients with Type 2 Diabetes, 
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Figure 2. The mRNA expression of TLR-2 (A), TLR-4 (B), NOD-1 (C), and S1RT-1 (D) at baseline in obese 
diabetes, after 6 weeks of 1.2 mg liraglutide, and 6 weeks after the stop of liraglutide. y  axis -
patients with type 2
r ACt
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DISCUSSION
Tn this pilot clinical investigation we provided 
new data that L can inhibit proinflammatory NF-kB 
pathway by increased SIRT1 expression in obese 
patients with type 2 DM improving metabolic 
profile.
Several years ago the conception for permanent 
activation of nuclear factor kB as a possible typical 
pathological process was provided supposing that 
NF-kB is the key molecule in the initiation and 
formation of “a vicious circle -  insulin resistance -  
inflammation -  atherosclerosis” [10].
An inflammatory process in the pathogenesis 
of insulin resistance in obesity and type 2 DM 
coupled to the IKKb/NF-kB pathway as a molecular 
mediator of insulin resistance and pharmacological 
target for insulin sensitization [11].
Our data support this point of view demons­
trating that obese patients with type 2 DM had the 
high expression of TLR-4. TLR-4 is the receptor 
for endotoxin and some lipoproteins. Lipopoly- 
saccharide-induced clinical inflammatory response 
were mediated by TLR-4 binding and led to the 
secretion of TNF-a. TNF-a is a NF-kB-induced 
gene product like IL-2, ceruloplasmin, etc.
Incretins or inhibitors dipeptidyl peptidase-IV 
(DPP-IV), such as exenatide, sitagliptin, liraglutide, 
are currently being used in the treatment of type 2 
DM [12; 13; 14]. Inhibitor DPP-IV sitagliptine 
exerted a potent anti-inflammatory effect due to 
suppression of intranuclear NF-kB binding and the 
expression of IKKb, CCR-2, TLR-2 and CD26 [3].
GLP-1 suppressed inflammation (soluble inter­
cellular adhesion molecule-1 and interleukin-6) in 
type 1 DM patients [15]. In animal model of 
allergic inflammation it was shown that GLP-1 
inactivates NF-kB possibly through PKA [16].
L as GLP-1 analogue exerts an anti-inflam­
matory effect on vascular endothelial cells by 
increasing nitric oxide production and exerts anti­
inflammatory action [12, 17]. L had a strong anti­
inflammatory effect on cultured human aortic 
endothelial cells due to its ability to increase 
intracellular Ca2" and activate CAMKKp, which in 
turn activates AMPK [18].
Our data showed that L decreased the mRNA 
expression of TNF-a, IkB, TLR2, TLR4, in peripheral 
blood MNC. These findings support the anti­
inflammatory activity of L directed to the NF-kB 
pathway and to the pattern recognition molecules.
TNF-a and TLR-4 induce serine phosphory­
lation of IRS-1 and are involved in insulin 
resistance pathogenesis [19]. Thus, L may be a 
potential insulin sensitizer. Recent data showed that
liraglutide anti-inflammatory effects depended on 
SIRT6 expression. Both endothelial progenitor cells 
and endothelial cells treated with high glucose 
(25 mmol/L) in the presence of GLP-1 (100 nmol/L 
liraglutide) presented a greater SIRT6 and a lower 
NF-kB expression as compared with cells treated 
only with high glucose. These findings establish 
the involvement of SIRT6 in the inflammatory 
pathways of diabetic atherosclerotic lesions and 
suggest its possible positive modulation by incretin, 
the effect of which is associated with morpho­
logical and compositional characteristics of a potential 
stable plaque phenotype [20].
From our point of view not only SIRT6 
realized liraglutide effects but also SIRT1. Sirtuin 1 
(SIRT1), a class III histone/protein deacetylase, is 
associated with aging and metabolism through 
maintaining inflammation via NF-kB. The up- 
regulation of NF-kB transcriptional activity and 
pro-inflammatory cytokine mRNA expression by 
p65 subunit of NF-kB and lipopolysaccharide were 
suppressed by SIRT1 [21]. Because of the central 
role of NF-kB in cytokine-mediated pancreatic 
3-cell damage, it was postulated that SIRT1 might 
work in pancreatic (3-cell damage models [22].
As a deacetylase target of Sirtl, nuclear 
factor-kappa B (NF-kB) regulates the significant 
cell biological activity including cell cycle, apoptosis, 
adhesion and angiogenesis through interacting with 
its downstream genes [23]. It has been reported that 
Sirtl could dcacetylate p65 subunit of NF-kB at lysine 
310 to inhibit its transcription physically [24].
In the animal models it was shown that L 
influenced SIRT 1 activity in obesity-induced 
chronic kidney injury [5], in TNF-a and hypoxia- 
stimulated H9c2 cells [6], in the infarcted heart 
[25], in non-alcoholic fatty liver disease [26], in 
streptozotocin-induced diabetic rats [7], and in the 
brain of type 2 diabetes rats [8].
Our data had shown the strong and long 
lasting effect of liraglutide on the expression of 
SIRT-1 in patients. Liraglutide increased SIRT-1 
expression significantly after 6 weeks of treatment 
and this effect was observed during 6 weeks after 
the end of treatment. Moreover, we observed the 
further decreasing of BMI, HbAlc, fasting glucose, 
total cholesterol, and ceruloplasmin. Taking into 
consideration the fact that SIRT-1 is involved in 
the epigenetic regulation of pathological pathways 
in many diseases, such as type 2 DM [9, 26, 27], 
we suppose that such liraglutide effect is mediated 
by epigenetic regulation.
Our investigation has several limitations. The 
data obtained are limited by the add-on design of 
clinical investigation, and further placebo-controlled
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trials are needed. A stronger calculation could be 
performed for statistical analysis to ensure the 
significance of L influence on SIRT1 expression in 
obese patients with type 2 DM.
Recent data contributed to epigenetic treatment 
of type 2 DM targeted on SIRT1-regulated and 
relevant for diabetes genes by L. SIRT1-targeted L 
activity found in peripheral blood mononuclear 
cells should be proved in other metabolic active 
tissues in patients with type 2 DM. The tight 
control of NF-kB pathway by SIRT1 needs further 
investigations.
CONCLUSIONS
Liraglutide exerts an anti-inflammatory effect 
as reflected in decreasing of TNF-a, IkB, TLR2,
TLR4, NODI mRNA within 6 weeks of treatment 
in peripheral blood mononuclear cells and over the 
period of 6 weeks after the end of treatment. Plasma 
ceruloplasmin, total cholesterol and fasting glucose 
concentrations also fall significantly. Long lasting 
effects of liraglutide can be mediated by epigenetic 
regulation of NF-kB pathway by SIRT-1. Liraglutide 
may therefore be potentially antiatherogenic and 
may have the ability of insulin sensitizer.
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Introducere. Ligaturidul (L) este un analog al hormonului glucagon-like 
peptide 1 ce stimuleaza secretia de insulina dependenta de glucozd p  care poate sd 
modifice expresia unor biomarkeri inflamatori. L poate influenta cascada 
inflamatorie mediate de NF-kB dar mecanismele acesteia raman ined neelucidate. 
Pe modele animate L influenteaza activitatea Sirtuineil (SIRTJ). Mai mult, studii 
recente arata faptul cd supraexprimarea SIRTJ ar putea avea un rol terapeutic 
impotriva progresiei complicatiilor diabetului. Scopul studiului a fast de a 
investiga efectele L asupra cascadei inflamatorii mediate de NF-kB p  SIRTJ la 
pacienti obezi cu diabet zaharat tip 2.
Materiale p  metode. Au fast in cl up in studiu 15 pacienti obezi cu diabet 
zaharat tip 2, toti au avut initial tratament cu metformin p  sulfaniluree. Toti 
pacientii au primit L 1.2 mg/zi timp de 6 sdptdmdni. Au fast prelevate probe 
biologice inaintea initierii tratamentului cu L, la oprirea tratamentului p  la 
6 sdptdmdni dupd oprirea tratamentului. Au fast izolate celulele mononucleate. 
Folosind tehnica RT-PCR, a fast analizata expresia ARN-ului mesager a TNF-a, 
TLR2, TLR4, NODI, IL-2 p  SIRTJ. Ceruloplasmina plasmatica a fast dozatd prin 
metode spectrofotometrice.
Rezultate. L poate bloc a activitatea NF-kB prin creperea espresiei SIRT1 la 
pacientii obezi cu diabet tip 2. Expresia ARNm a TNF-a, IkB, TLR2, TLR4 p  cea 
plasmatica a ceruloplasminei a scdzut dupd 6 sdptdmdni cu L. Expresia IL-2 p  a 
NOD nu s-au modificat. Expresia ARNm a SIRT1 nu a crescut. La 6 sdptdmdni 
dupd incetarea tratamentului cu L, expresia TNF-a, IkB, TLR2, TLR4, NODI, 
SIRT1 p  a ceruloplasminei plasmatice nu s-a modificat spre valorile de baza. In 
schimb, nivelul IL-2 a scdzut comparat cu nivelul de baza.
Concluzii. L are un effect antiinflamator prin sedderea expresiei NF-kB p  
creperea expresiei SIRT1, scazand expresia citokinelor pro-inf amatorii. Efectele 
de duratd ale L pot fi explicate prin modifiedri epigenetice a edii NF-kB via SRT1.
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